Biologic therapy in Crohn's disease: Review of the evidence

Reviews in Gastroenterological Disorders

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Loftus Jr , Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adalimumab; Certolizumab pegol; Crohn's disease; Infliximab; TNF

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; AUTOIMMUNITY; BACTERIAL INFECTION; CANCER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER FAILURE; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOMA; MYCOSIS; OPTIC NEURITIS; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS; UNITED STATES; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CROHN DISEASE; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 33847606974     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004;4(suppl 3):S18-S24.
2. Remicade® (infliximab) for IV injection [prescribing information]. Malvern. PA: Centocor, Inc.; 2006.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimertc monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
5. Hyams J, Crandall W, Kugathasan S, et al. Maintenance therapy with infliximab every 8 weeks is superior to every 12 weeks in maintaining response and remission in pediatric patients with moderately to severely active Crohn's disease [abstract]. Gastroenterology. 2006;130(4 suppl 2):A12.
6. Humira® (adalimumab) [prescribing information]. North Chicago, IL: Abbott Laboratories: 2006.
7. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
8. Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study [abstract]. Am J Gastroenterol. 2005;100 (suppl 9):S311.
9. Sandborn WJ, Hanauer SB, Lukas M, et al. Remission and clinical response induced and maintained in patients with active Crohn's disease treated for 1-year open-label with adalimumab [abstract]. Am J Gastroenterol. 2005;100(suppl 9):S316-S317.
10. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: results of the CHARM trial [abstract]. Gastroenterology. 2006;131:950.
11. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
12. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1) [abstract]. Gastroenterology. 2006;130(4 suppl 2):A 107-A 108.
13. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanised anti-TNF pegylated FAb′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (Precise) [abstract]. Gut. 2005;54(suppl VII):A82.
14. Reddy JG, Loftus EV. Safety of infliximab and other biological agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855.
15. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
16. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.